Eintrag weiter verarbeiten
Valproic Acid–induced Hepatopathy: Nine New Fatalities in Germany from 1994 to 2003
Gespeichert in:
Personen und Körperschaften: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Titel: |
Valproic Acid–induced Hepatopathy: Nine New Fatalities in Germany from 1994 to 2003 |
In: | Epilepsia, 47, 2006, 12, S. 2027-2031 |
veröffentlicht: |
Wiley
|
Umfang: | 2027-2031 |
ISSN: |
0013-9580 1528-1167 |
DOI: | 10.1111/j.1528-1167.2006.00846.x |
Zusammenfassung: | <jats:p><jats:bold>Summary: </jats:bold> <jats:italic>Purpose:</jats:italic> Valproic acid (VPA) is an antiepileptic drug (AED) commonly used for generalized and focal epilepsies. We provide an update on hepatotoxic side effects in Germany between 1994 and 2003.</jats:p><jats:p> <jats:italic>Methods:</jats:italic> We mailed a questionnaire to all members of the German Section of the International League Against Epilepsy, asking for VPA‐induced side effects, especially severe side effects such as hepatopathy.</jats:p><jats:p> <jats:italic>Results:</jats:italic> As a result of our questionnaire, we found 31 cases of reversible hepatotoxicity and nine cases of lethal hepatopathies in Germany from 1994 to 2003.</jats:p><jats:p> <jats:italic>Conclusions:</jats:italic> The outcome of patients with severe hepatotoxicity is better than that in the past. The risk of a VPA‐induced hepatopathy is not limited to patients younger than 2 years, receiving polytherapy, or patients with congenital or acquired metabolic diseases.</jats:p> |
Format: | E-Article |
Quelle: | Wiley (CrossRef) |
Sprache: | Englisch |